Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic
change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in
non-small cell lung cancer. After a 10 to 14 months median progression-free survival with the
treatment of first generation EGFR TKI, half of patients will get disease progression.For
patients progression after treated with first line EGFR TKI and second line double bullets
chemotherapy or chemotherapy then EGFR TKI, optimal third line therapy is quite critical
important for benefit patients' survival. We conducted this study was aimed to compare the
efficacy and toxicity between osimertinib and docetaxel-bevacizumab as the third line therapy
in patients with local advanced or metastatic non-squamous cell lung cancer.